Baxter International (BAX) Cost of Revenue (2009 - 2026)

Baxter International (BAX) has 18 years of Cost of Revenue data on file, last reported at $1.8 billion in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 2.61% year-over-year to $1.8 billion in Q1 2026; TTM through Mar 2026 was $7.0 billion, a 2.13% increase from a year earlier, with the FY2025 full-year figure at $7.9 billion, up 18.24% from the prior year.
• Cost of Revenue for Q1 2026 stood at $1.8 billion, up from $1.8 billion in the prior quarter.
• Over the last five years, Cost of Revenue for BAX reached as high as $2.6 billion in Q2 2023 and fell as low as -$1.2 billion in Q4 2023.
• Historically, Cost of Revenue has averaged $1.7 billion across 5 years, with a median of $2.0 billion in 2024.
• Across the five-year window, Cost of Revenue sank 131.0% in 2022 and jumped 247.65% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at -$575.0 million in 2022, then slumped by 111.3% to -$1.2 billion in 2023, then soared by 247.65% to $1.8 billion in 2024, then decreased by 1.67% to $1.8 billion in 2025, then advanced by 2.61% to $1.8 billion in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $1.8 billion in Q1 2026, $1.8 billion in Q1 2025, and $1.8 billion in Q4 2024.